Part 2 of 3: The Night the Organ Monopoly Proved It Was Real

Healthcare Barbell Series Date: February 24, 2026 : Earnings Day Ticker: (TMDX) TransMedics Group Series: Healthcare Barbell, Part 2 of 3 Action: PATIENT ACCUMULATE - Limit Orders $120–$125 Summary: Tonight, TransMedics ended the debate. Q4 revenue of $160.8M came in 3% above consensus. Full-year 2025 revenue hit $605.5M, up 37%. The company completed 5,139 organ cases - 38% more than the year before - using 22 aircraft it owns outright. ROIC crossed above WACC for the first time. The thesis is confirmed. But the stock surged 6.7% after hours, which means the entry is not tonight. The buy zone is $120–$125. If you are building a Healthcare Barbell alongside Part 1 ($GILD), this is the growth end of the bar - and patience here is part of the position. Initial target: 0.5% on first fill, building to 1–1.5%. Tonight's Numbers, and Why They Matter Beyond the Beat Forty thousand people in the United States are waiting for an organ right now. Every ten minutes, another name gets added to that list. Every day, seventeen of them run out of time. That is not an abstraction. That is what TransMedics Group is actually working against - and what made tonight's earnings report feel less like a quarterly disclosure and more like a progress report on something genuinely important. Revenue: $160.8 million for Q4, up 32% year-over-year, against a consensus of $156 million. Full year: $605.5 million, up 37% from $441.5 million in 2024. OCS case volume: 5,139 U.S. cases completed in 2025, up 38% from 3,735 the prior year. 2026 guidance: $727 million to $757 million, 20 to 25% growth, with the $742 million midpoint coming in above the $725 million Street estimate. The one nuance worth flagging immediately: reported net income of $190.3 million for the full year includes an $83.8 million one-time tax benefit from a deferred asset valuation allowance release. Strip that out and clean Q4 EPS was approximately $0.43 per diluted share - still a beat against the $0.39 consensus, just not the headline number. Operating income is the signal, not the reported figure. The stock is up 6.7% in after-hours trading as of this writing. That pop is not an entry point. It is the market paying up for information that patient investors already held. The limits go in tomorrow. The Graduation No One Celebrated In Part 1 of this Healthcare Barbell series, we covered Gilead Sciences - a company that graduated from an HIV specialist into a diversified oncology and antiviral platform, and the market has been slow to reprice that transformation. TMDX completed a different kind of graduation tonight: from speculative medical device company to verified logistics monopoly. That distinction matters more than it sounds. A speculative company gets priced on what it might become. A verified monopoly gets priced on what it demonstrably is and what the compounding of that thing implies. Until tonight, (TMDX) was priced somewhere between those two descriptions, with investors rightly wondering whether the operating leverage story was real or whether the aviation fleet would keep eating earnings. Tonight answered that question. The Organ Care System - the device itself - is a sophisticated perfusion platform that keeps donor livers, hearts, and lungs warm and functioning during transport. It replaced the "ice in a cooler" method that has been standard since the 1960s, and it is genuinely superior: warmer ischemia times, better organ viability, fewer discard events. The patents are real. The clinical evidence is real. But the device is only half of what TransMedics built. The other half is the National OCS Program call it the organ network. It is the operating infrastructure that turns a device sale into a contracted service: 22 owned aircraft, employed perfusionists who fly with every organ, end-to-end logistics coordination between donor hospital and receiving surgical team, and bundled billing that replaces unpredictable third-party charter costs ($